On June 15, 2026, Carmen Bozic, Executive Vice President and Chief Medical Officer at Vertex Pharmaceuticals Inc VRTX, sold 4,062 shares of the company. Following this transaction, the insider now owns 16,953 shares of Vertex Pharmaceuticals Inc. The details of this transaction can be found in the SEC Filing.
Vertex Pharmaceuticals Inc is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company focuses on developing and commercializing therapies for cystic fibrosis and has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta-thalassemia, pain, type 1 diabetes, and alpha-1 antitrypsin deficiency.
The insider transaction history for Vertex Pharmaceuticals Inc indicates that there have been 2 insider buys and 49 insider sells over the past year. Over the same period, Carmen Bozic has sold a total of 23,110 shares and has not purchased any shares.
As of the date of the recent transaction, shares of Vertex Pharmaceuticals Inc were trading at $450 each, giving the company a market cap of $116,494.151 million. The company’s price-earnings ratio stands at 27.22, which is higher than the industry median of 27.17 but lower than the company’s historical median price-earnings ratio.
With a trading price of $450 and a GF Value of $501.43, Vertex Pharmaceuticals Inc has a price-to-GF-Value ratio of 0.9, indicating that the stock is fairly valued based on its GF Value. The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on historical multiples, a GuruFocus adjustment factor, and future estimates of business performance from Morningstar analysts.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].